The Human Microbiome Therapeutics study sheds light on industry profiles across several countries and regions. The extensive document is a rich source of information on market size, share and growth rate. The industry profiles discussed in the Human Microbiome Therapeutics report further identifies market segmentation, profit, and competitive landscape and offers forecast information on industry performance and trends for the period, 2020 to 2027. The detailed report offers comprehensive analyses about a particular market situation within a geographic region..
The Global Human Microbiome Therapeutics Market is estimated to garner a valuation of USD 1,098.4 Million by 2027, according to the latest assessment by Emergen Research. The industry is speculated to grow substantially with the rising prominence of the market in the sphere of personalized medicine & nutrition. Moreover, technological improvements in the metagenomics sector and the therapeutic system would also impel market growth in the forecast duration.
However, the surging costs of equipment and infrastructure, as well as challenging laboratory bacteria development & isolation procedures, are predicted to restrain market growth in the following years.
For industry-leading market insights, visit the link below:
https://www.emergenresearch.com/industry-report/human-microbiome-therapeutics-market
Emergen Research has categorized the Global Human Microbiome Therapeutics Market based on product, approach, therapeutic area, disease, and region:
- Product Outlook (Revenue, USD Million; 2017-2027)
- Prescription Drugs
- Medical Foods
- Probiotics
- Prebiotics
- Approach Outlook (Revenue, USD Million; 2017-2027)
- Microbial Consortia
- Small Molecule Therapies
- Phage Cocktail
- Genetically Modified Single Strain Bacteria
- Microbial Ecosystems
- Single Strain Whole Bacteria
- Therapeutic Area Outlook (Revenue, USD Million; 2017-2027)
- Oncology
- Dermatological Disorders
- Autoimmune Disorders
- Infectious Disease
- Metabolic Disorders
- Others
- Disease Outlook (Revenue, USD Million; 2017-2027)
- Irritable Bowel Syndrome
- Crohn’s Disease
- Diabetes
- difficile
- Others
- Regional Outlook (Revenue, USD Million; 2017-2027)
- North America
- S.
- Canada
- Mexico
- Europe
- Germany
- K.
- France
- BENELUX
- Rest of Europe
- Asia Pacific
- China
- Japan
- South Korea
- India
- Rest of APAC
- Latin America
- Brazil
- Rest of LATAM
- Middle East & Africa
- Saudi Arabia
- A.E.
- Rest of MEA
- North America
Key Highlights From The Report
- In August 2019, BiomX Ltd. finished the construction of a new cutting-edge production facility in Ness Ziona, intended for the clinical development of candidate phage products for the firm, which could be extended in the future to meet the demands of commercial manufacturing. This development has been significant for clinical development in the present live biotherapeutics landscape that encompasses phages and human-derived cells & bacteria.
- North America is predicted to dominate the overall market share with the rising consumption of dietary supplements in the region. Technologically specialized research establishments to facilitate the development of experimental therapeutics, escalating healthcare expenditure, and the increasing number of health-conscious consumers are assisting the growth of the regional market.
- Key participants include Oxidien Pharmaceuticals, LLC, DermBiont, Inc, LNC Therapeutics SA, Carbiotix AB, Embion Technologies SA, BiomX Ltd., CoreBiome, Inc., Biotagenics Inc., Commense Inc, and Finch Therapeutics, among others.
